Work

Durability of Response in Metastatic Melanoma Patients after Combined Treatment with Radiation Therapy and Ipilimumab

Year: 2020

Type: article

Abstract: AIM: We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term update on patients with complete response (CR) or partial response (PR). PATIENTS & METHODS: We continued to follow these patients with serial imaging including computed tomography, PET or MRI. RESULTS: Two of the three patients with CR are still alive and without evidence of melanoma but with chronic treatment-induced hypophysitis. The third patient died of hepatocellular carcinoma, but with no evidence of melanoma. Among the three patients with PR, two achieved CR after pembrolizumab monotherapy. CONCLUSION: This long-term follow up reveals the striking durability of the CRs, which appears to correlate with a grade 2-3 hypophysitis.

Source: Melanoma Management

DOI: 10.2217/mmt-2019-0020

Authors: Quaovi H Sodji, Paulina M Gutkin, Susan M Swetter, Sunil A Reddy, Susan M Hiniker, Susan J Knox

Institutions: Stanford Medicine, Stanford Cancer Institute, Stanford University, VA Palo Alto Health Care System

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,415